Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
93 participants
INTERVENTIONAL
2014-11-30
2015-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Dose Finding Study in Physically Frail Elderly to Measure 25(OH) Vitamin D Levels After Supplementation With Hy.D Calcifediol 25 SD/S and Vitamin D3
NCT01868945
Pilot Pharmacokinetic Study of Daily Versus Monthly High-Dose Cholecalciferol Supplementation
NCT01079923
The Variability of 25-hydroxyvitamin D Response From Crystalline 25-hydroxyvitamin D3
NCT01633658
A Prospective Open-label Comparison of Two Vitamin D3 Repletion Strategies in Vitamin D Deficient Patients
NCT01650883
Effects of Vitamin D3 Versus 25OHD3 on Mineral Metabolism and Immune Function
NCT02091219
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
25(OH)D3 (Calcifediol Hy.D) 10 mcg
25(OH)D3 (Calcifediol Hy.D), Dose: 10 mcg, 1 capsule/day before breakfast, Duration: 6 months
25(OH)D3 (Calcifediol Hy.D) 10 mcg
25(OH)D3 (Calcifediol Hy.D)
25(OH)D3 (Calcifediol Hy.D) 15 mcg
25(OH)D3 (Calcifediol Hy.D), Dose: 15 mcg, 1 capsule/day before breakfast, Duration: 6 months
25(OH)D3 (Calcifediol Hy.D) 15 mcg
25(OH)D3 (Calcifediol Hy.D)
25(OH)D3 (Calcifediol Hy.D) 20 mcg
25(OH)D3 (Calcifediol Hy.D), Dose: 20 mcg, 1 capsule/day before breakfast, Duration: 6 months
25(OH)D3 (Calcifediol Hy.D) 20 mcg
25(OH)D3 (Calcifediol Hy.D)
Vitamin D3 (Cholecalciferol) 20 mcg
Vitamin D3 (Cholecalciferol), Dose: 20 mcg, 1 capsule/day before breakfast, Duration: 6 months
Vitamin D3 (Cholecalciferol) 20 mcg
Vitamin D3 (Cholecalciferol)
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
25(OH)D3 (Calcifediol Hy.D) 10 mcg
25(OH)D3 (Calcifediol Hy.D)
25(OH)D3 (Calcifediol Hy.D) 15 mcg
25(OH)D3 (Calcifediol Hy.D)
25(OH)D3 (Calcifediol Hy.D) 20 mcg
25(OH)D3 (Calcifediol Hy.D)
Vitamin D3 (Cholecalciferol) 20 mcg
Vitamin D3 (Cholecalciferol)
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Healthy postmenopausal women \>50 years in age, who have not experienced a menstrual bleeding for a minimum of 12 months
* BMI between 20-32 kg/m2
* Subject understands the study procedures and signs the informed consent to participate in the study
* Subject has clear understanding of the English language
* Caucasian ethnicity
* Willingness to avoid direct sun exposure and to restrict travel to sunny climates during the whole study period.
Exclusion Criteria
* Subjects with a history of hypercalcemia (Serum calcium adjusted for albumin of \> 2.6 nmol/l)
* Supplemental calcium intake beyond 500 mg per day during the entire study and follow up
* Any vitamin D supplementation within 2 months before the baseline blood draw and during the entire study and follow up
* Subject has gastrointestinal malabsorption (from coeliac disease, colitis, surgery etc.)
* Subject has kidney disease or liver disease
* Medication: Bisphosphonate or Parathyroid Hormone (PTH) treatment, use of steroids in any form, anticonvulsants, antibiotics, antipsychotics, use of any drug that alters fat absorption, e.g. Xenical (Ali).
* Use of Hormone Replacement Therapy (HRT) within the previous 6 months
* Subject has signs of acute or severe illness (i.e. unintentional weight loss, night sweats etc.)
* Subject has a known allergy or sensitivity to the investigational products or any ingredients of the investigational products
* Subject heavily consumes alcohol containing products defined as greater than (\>) 3 drinks for men or 2 drinks for women (1 drink is 11 grams of alcohol or equivalence of 12 oz beer, 5 oz wine, or 1.5 oz distilled spirits) of alcoholic beverages per day
* Subject has donated more than 300 mL of blood during the last three months prior to screening
* Participating in another clinical trial
* Women who are premenopausal
* Subjects with active current psychiatric illness or condition which is likely to interfere with the subject's ability to understand the requirements of the biomedical research project
* Sunbed users will be excluded from the study.
* (Expected) increase in exposure to sunlight (e.g. a planned holiday of more than eight days, a beach holiday or a holiday outside Europe) in the study period of day 01 until day 28.
50 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Leatherhead Food Research
INDUSTRY
DSM Nutritional Products, Inc.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Sarah Hull, MSc
Role: PRINCIPAL_INVESTIGATOR
Leatherhead Food Research
References
Explore related publications, articles, or registry entries linked to this study.
Graeff-Armas LA, Bendik I, Kunz I, Schoop R, Hull S, Beck M. Supplemental 25-Hydroxycholecalciferol Is More Effective than Cholecalciferol in Raising Serum 25-Hydroxyvitamin D Concentrations in Older Adults. J Nutr. 2020 Jan 1;150(1):73-81. doi: 10.1093/jn/nxz209.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
127927
Identifier Type: OTHER
Identifier Source: secondary_id
2013-04-17-HDPK
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.